Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Stanozolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.64 |
| ▸ | ESR1 | P03372 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stanozolol SCHEMBL44099 | 1.00 | CYP2C19 (0.64) | CYP2C19ADORA3ESR1CYP2D6CYP2C9 | |
| Stanozolol SCHEMBL6151066 | 1.00 | CYP2C19 (0.64) | CYP2C19ADORA3ESR1CYP2D6CYP2C9 | |
| Stanozolol SCHEMBL19645424 | 1.00 | CYP2C19 (0.64) | CYP2C19ADORA3ESR1CYP2D6CYP2C9 | |
| Oxymetholone SCHEMBL2024270 | 0.89 | ADORA3 (0.74) | CYP2C19ADORA3ESR1CYP2D6CYP2C9 | |
| SCHEMBL27046793 | 0.89 | CYP2C19 (0.52) | CYP2C19ADORA3ESR1CYP2D6CYP2C9 | |
| Stanozolol SCHEMBL13724751 | 0.86 | SHBG (0.61) | CYP2C19ADORA3ESR1CYP2D6CYP2C9 | |
| SCHEMBL21392304 | 0.86 | CYP2C19 (0.49) | CYP2C19ADORA3ESR1CYP2D6CYP2C9 | |
| Stanozolol SCHEMBL329926 | 0.85 | LMNA (0.63) | CYP2C19ADORA3ESR1CYP2D6CYP2C9 | |
| SCHEMBL27046806 | 0.84 | CYP2C19 (0.45) | CYP2C19ADORA3ESR1CYP2D6CYP2C9 | |
| SCHEMBL27046803 | 0.84 | CYP2C19 (0.45) | CYP2C19ADORA3ESR1CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11013813-B2 | Conjugates of stanozolol and hyaluronic acid | ACME DRUGS S.R.L. (IT) | 2021-05-25 | — | — | US | disclosed |
| US-20210038735-A1 | CONJUGATES OF STANOZOLOL AND HYALURONIC ACID | ACME DRUGS S.R.L. (IT) | 2021-02-11 | — | — | US | disclosed |
| US-8722651-B2 | Methods and products for treatment of diseases | AMPIO PHARMACEUTICALS, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722651-B2 | Methods and products for treatment of diseases | AMPIO PHARMACEUTICALS, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8586568-B2 | Methods and products for treatment of diseases | AMPIO PHARMACEUTICALS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586568-B2 | Methods and products for treatment of diseases | AMPIO PHARMACEUTICALS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20110171306-A1 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | AMPIO PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20110171307-A1 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | AMPIO PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20110171306-A1 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | AMPIO PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20110171307-A1 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | AMPIO PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20070111972-A1 | \"METHODS AND PRODUCTS FOR TREATMENT OF DISEASES\ | DMI BIOSCIENCES, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070111972-A1 | \"METHODS AND PRODUCTS FOR TREATMENT OF DISEASES\ | DMI BIOSCIENCES, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007009087-A2 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | DMI BIOSCIENCES, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210038735-A1 | CONJUGATES OF STANOZOLOL AND HYALURONIC ACID | CD44, HSD17B2, HSD17B1 | AR 173/4885CYP2C19 956/4885ADORA3 2983/4885 |
| US-20110171306-A1 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | VEGFA, PGF, BDNF | AR 1551/4885CYP2C19 1247/4885ADORA3 1398/4885 |
| US-20070111972-A1 | \"METHODS AND PRODUCTS FOR TREATMENT OF DISEASES\ | PGF, VEGFA, BDNF | AR 2029/4885CYP2C19 983/4885ADORA3 2062/4885 |
| US-11013813-B2 | Conjugates of stanozolol and hyaluronic acid | CD44, HSD17B2, HSD17B1 | AR 173/4885CYP2C19 956/4885ADORA3 2983/4885 |
| US-20110171307-A1 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | VEGFA, PGF, BDNF | AR 1551/4885CYP2C19 1247/4885ADORA3 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.